alanine has been researched along with Disease Exacerbation in 59 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Brivanib is an oral, tyrosine kinase inhibitor against vascular endothelial growth factor (VEGF) and fibroblast growth factor receptor (FGFR)." | 6.84 | A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study. ( Aghajanian, C; Bonebrake, AJ; Chafe, W; Chan, JK; Deng, W; Gaillard, S; Hicks, M; Higgins, RV; Monk, BJ; Ramirez, PT; Tewari, KS, 2017) |
| "Brivanib is an oral, tyrosine kinase inhibitor against vascular endothelial growth factor (VEGF) and fibroblast growth factor receptor (FGFR)." | 2.84 | A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study. ( Aghajanian, C; Bonebrake, AJ; Chafe, W; Chan, JK; Deng, W; Gaillard, S; Hicks, M; Higgins, RV; Monk, BJ; Ramirez, PT; Tewari, KS, 2017) |
| "Proteinuria is also now recognized as a common finding in individuals living with HIV." | 2.55 | Renal effects of novel antiretroviral drugs. ( Jones, R; Levy, JB; Milburn, J, 2017) |
| "Safinamide (Xadago™) is an oral α-aminoamide derivative marketed for the treatment of Parkinson's disease (PD)." | 2.52 | Clinical pharmacology review of safinamide for the treatment of Parkinson's disease. ( Abreu, D; Fabbri, M; Ferreira, JJ; Rosa, MM, 2015) |
| "Safinamide (NW-1015) is a novel drug with multiple actions." | 2.50 | Safinamide for the treatment of Parkinson's disease. ( Borgohain, R; Jabeen, SA; Kandadai, RM; Kanikannan, MA, 2014) |
| "Current therapy for Parkinson's disease (PD) is primarily directed at reversing the motor symptoms that are the consequence of dopamine deficiency and includes levodopa, dopamine agonists and monoamine oxidase (MAO) B inhibitors." | 2.46 | Safinamide in the treatment of Parkinson's disease. ( Schapira, AH, 2010) |
| "To investigate disease progression and aging, we utilized young (1 month old) and old (21-25 months old) mdx and wild-type tongue muscles." | 1.91 | Biomarkers for Duchenne muscular dystrophy progression: impact of age in the mdx tongue spared muscle. ( Chamberlain, JS; Ferretti, R; Lorena, MDSV; Matsumura, CY; Nagana Gowda, GA; Odom, GL; Santos, EKD, 2023) |
| "We describe a case of coronavirus disease 2019 (COVID-19) in a patient with mixed cellularity classical Hodgkin lymphoma (cHL) undergoing brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) therapy." | 1.62 | Prolonged persistence of SARS-CoV-2 infection during A+AVD therapy for classical Hodgkin's lymphoma: A case report. ( Fujii, H; Goda, S; Hiraoka, N; Matsumoto, Y; Matsuyama, A; Omura, A; Ono, S; Shiotsu, S; Suga, Y; Sugitani, M; Takumi, C; Tanaka, S; Tsuji, T; Yuba, T, 2021) |
| "Effective therapies to treat coronavirus disease 2019 (COVID-19) are urgently needed." | 1.56 | Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. ( Anzick, S; Barbian, K; Bosio, CM; Cihlar, T; de Wit, E; Feldmann, F; Hanley, PW; Leighton, I; Lovaglio, J; Martens, C; Meade-White, K; Munster, VJ; Okumura, A; Pérez-Pérez, L; Porter, DP; Saturday, G; Schulz, J; Schwarz, B; Scott, DP; van Doremalen, N; Williamson, BN; Yinda, CK, 2020) |
| " We found that S421 phosphorylation mitigates neurodegeneration by increasing proteasome-dependent turnover of mHTT and reducing the presence of a toxic mHTT conformer." | 1.43 | Serine 421 regulates mutant huntingtin toxicity and clearance in mice. ( Daub, AC; Finkbeiner, S; Gu, X; Humbert, S; Kratter, IH; Lau, A; Masliah, E; Osmand, A; Saudou, F; Steffan, JS; Tsvetkov, AS; Weiberth, KF; Yang, XW; Zahed, H, 2016) |
| "We hypothesized that the progression of bladder cancer could be accompanied by changes in cells glycolytic profile." | 1.42 | The progression from a lower to a higher invasive stage of bladder cancer is associated with severe alterations in glucose and pyruvate metabolism. ( Alves, MG; Conde, VR; Nunes, AR; Oliveira, PF; Pereira, JA; Ramalhosa, E; Rocha, CS; Silva, BM, 2015) |
| "Increased susceptibility to dilated cardiomyopathy has been observed in patients carrying mutations in the SCN5A gene, but the underlying mechanism remains unclear." | 1.35 | Molecular and clinical characterization of a novel SCN5A mutation associated with atrioventricular block and dilated cardiomyopathy. ( Fan, Z; Gao, L; Ge, J; Jia, J; Li, Y; Paajanen, V; Su, C; Sun, A; Wang, K; Wang, S; Yang, Z; Zou, Y, 2008) |
| "Amyotrophic lateral sclerosis (ALS), a multifactorial disease characterized by diffuse motor neuron degeneration, has proven to be a difficult target for stem cell therapy." | 1.32 | Intravenous administration of human umbilical cord blood cells in a mouse model of amyotrophic lateral sclerosis: distribution, migration, and differentiation. ( Chen, N; Davis, CD; Garbuzova-Davis, S; Hudson, JE; Justen, EB; Lane, JC; Sanberg, PR; Saporta, S; Willing, AE; Zigova, T, 2003) |
| "Free carnitine levels were progressively decreased at 3 w (74% of control values) and at 6 w (57% of control values)." | 1.29 | Cardiac energy metabolism at several stages of adriamycin-induced heart failure in rats. ( Ishii, Y; Kawasaki, N; Lee, JD; Shimizu, H; Ueda, T, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.69) | 18.2507 |
| 2000's | 15 (25.42) | 29.6817 |
| 2010's | 24 (40.68) | 24.3611 |
| 2020's | 19 (32.20) | 2.80 |
| Authors | Studies |
|---|---|
| Larson, D | 1 |
| Simuni, T | 1 |
| Gottlieb, RL | 1 |
| Vaca, CE | 1 |
| Paredes, R | 1 |
| Mera, J | 1 |
| Webb, BJ | 1 |
| Perez, G | 1 |
| Oguchi, G | 1 |
| Ryan, P | 1 |
| Nielsen, BU | 1 |
| Brown, M | 1 |
| Hidalgo, A | 1 |
| Sachdeva, Y | 1 |
| Mittal, S | 1 |
| Osiyemi, O | 1 |
| Skarbinski, J | 1 |
| Juneja, K | 1 |
| Hyland, RH | 1 |
| Osinusi, A | 1 |
| Chen, S | 1 |
| Camus, G | 1 |
| Abdelghany, M | 1 |
| Davies, S | 1 |
| Behenna-Renton, N | 1 |
| Duff, F | 1 |
| Marty, FM | 1 |
| Katz, MJ | 1 |
| Ginde, AA | 1 |
| Brown, SM | 1 |
| Schiffer, JT | 1 |
| Hill, JA | 1 |
| Falcone, M | 1 |
| Suardi, LR | 1 |
| Tiseo, G | 1 |
| Barbieri, C | 1 |
| Giusti, L | 1 |
| Galfo, V | 1 |
| Forniti, A | 1 |
| Caroselli, C | 1 |
| Della Sala, L | 1 |
| Tempini, S | 1 |
| Okoye, C | 1 |
| Monzani, F | 1 |
| Menichetti, F | 1 |
| Shytaj, IL | 1 |
| Fares, M | 1 |
| Gallucci, L | 1 |
| Lucic, B | 1 |
| Tolba, MM | 1 |
| Zimmermann, L | 1 |
| Adler, JM | 1 |
| Xing, N | 1 |
| Bushe, J | 1 |
| Gruber, AD | 1 |
| Ambiel, I | 1 |
| Taha Ayoub, A | 1 |
| Cortese, M | 1 |
| Neufeldt, CJ | 1 |
| Stolp, B | 1 |
| Sobhy, MH | 1 |
| Fathy, M | 1 |
| Zhao, M | 1 |
| Laketa, V | 1 |
| Diaz, RS | 1 |
| Sutton, RE | 1 |
| Chlanda, P | 1 |
| Boulant, S | 1 |
| Bartenschlager, R | 1 |
| Stanifer, ML | 1 |
| Fackler, OT | 1 |
| Trimpert, J | 1 |
| Savarino, A | 1 |
| Lusic, M | 1 |
| Heyer, A | 1 |
| Günther, T | 1 |
| Robitaille, A | 1 |
| Lütgehetmann, M | 1 |
| Addo, MM | 1 |
| Jarczak, D | 1 |
| Kluge, S | 1 |
| Aepfelbacher, M | 1 |
| Schulze Zur Wiesch, J | 1 |
| Fischer, N | 1 |
| Grundhoff, A | 1 |
| Lorena, MDSV | 1 |
| Santos, EKD | 1 |
| Ferretti, R | 1 |
| Nagana Gowda, GA | 1 |
| Odom, GL | 1 |
| Chamberlain, JS | 1 |
| Matsumura, CY | 1 |
| Singh, V | 1 |
| Mishra, VN | 1 |
| Prajapati, GD | 1 |
| Ampapathi, RS | 1 |
| Thakur, MK | 1 |
| Li, H | 1 |
| Liu, Z | 1 |
| Ge, J | 2 |
| Williamson, BN | 1 |
| Feldmann, F | 1 |
| Schwarz, B | 1 |
| Meade-White, K | 1 |
| Porter, DP | 1 |
| Schulz, J | 1 |
| van Doremalen, N | 1 |
| Leighton, I | 1 |
| Yinda, CK | 1 |
| Pérez-Pérez, L | 1 |
| Okumura, A | 1 |
| Lovaglio, J | 1 |
| Hanley, PW | 1 |
| Saturday, G | 1 |
| Bosio, CM | 1 |
| Anzick, S | 1 |
| Barbian, K | 1 |
| Cihlar, T | 1 |
| Martens, C | 1 |
| Scott, DP | 1 |
| Munster, VJ | 1 |
| de Wit, E | 1 |
| Giovane, RA | 1 |
| Rezai, S | 1 |
| Cleland, E | 1 |
| Henderson, CE | 1 |
| Yokoyama, Y | 1 |
| Briasoulis, A | 1 |
| Takagi, H | 1 |
| Kuno, T | 1 |
| Díaz, E | 1 |
| Amézaga Menéndez, R | 1 |
| Vidal Cortés, P | 1 |
| Escapa, MG | 1 |
| Suberviola, B | 1 |
| Serrano Lázaro, A | 1 |
| Marcos Neira, P | 1 |
| Quintana Díaz, M | 1 |
| Catalán González, M | 1 |
| Fei, Z | 1 |
| Lijuan, Y | 1 |
| Jing, Z | 1 |
| Xi, Y | 1 |
| Yuefen, P | 1 |
| Shuwen, H | 1 |
| Quintana-Ortega, C | 1 |
| Remesal, A | 1 |
| Ruiz de Valbuena, M | 1 |
| de la Serna, O | 1 |
| Laplaza-González, M | 1 |
| Álvarez-Rojas, E | 1 |
| Udaondo, C | 1 |
| Alcobendas, R | 1 |
| Murias, S | 1 |
| Trkulja, V | 1 |
| Banai, A | 1 |
| Taieb, P | 1 |
| Furie, N | 1 |
| Hochstadt, A | 1 |
| Merdler, I | 1 |
| Sapir, O | 1 |
| Granot, Y | 1 |
| Lupu, L | 1 |
| Ghantous, E | 1 |
| Borohovitz, A | 1 |
| Gal-Oz, A | 1 |
| Ingbir, M | 1 |
| Arbel, Y | 1 |
| Banai, S | 1 |
| Topilsky, Y | 1 |
| Lichter, Y | 1 |
| Szekely, Y | 1 |
| Fujii, H | 1 |
| Tsuji, T | 1 |
| Sugitani, M | 1 |
| Matsumoto, Y | 1 |
| Yuba, T | 1 |
| Tanaka, S | 1 |
| Suga, Y | 1 |
| Matsuyama, A | 1 |
| Goda, S | 1 |
| Omura, A | 1 |
| Shiotsu, S | 1 |
| Takumi, C | 1 |
| Ono, S | 1 |
| Hiraoka, N | 1 |
| Kutsuna, S | 1 |
| Ansems, K | 1 |
| Grundeis, F | 1 |
| Dahms, K | 1 |
| Mikolajewska, A | 1 |
| Thieme, V | 1 |
| Piechotta, V | 1 |
| Metzendorf, MI | 1 |
| Stegemann, M | 1 |
| Benstoem, C | 1 |
| Fichtner, F | 1 |
| Chan, JK | 1 |
| Deng, W | 1 |
| Higgins, RV | 1 |
| Tewari, KS | 1 |
| Bonebrake, AJ | 1 |
| Hicks, M | 1 |
| Gaillard, S | 1 |
| Ramirez, PT | 1 |
| Chafe, W | 1 |
| Monk, BJ | 1 |
| Aghajanian, C | 1 |
| Wasinger, C | 1 |
| Hofer, A | 1 |
| Spadiut, O | 1 |
| Hohenegger, M | 1 |
| Gaugg, MT | 1 |
| Engler, A | 1 |
| Bregy, L | 1 |
| Nussbaumer-Ochsner, Y | 1 |
| Eiffert, L | 1 |
| Bruderer, T | 1 |
| Zenobi, R | 1 |
| Sinues, P | 1 |
| Kohler, M | 1 |
| You, W | 1 |
| Li, Z | 1 |
| Jing, C | 1 |
| Qian-Wei, X | 1 |
| Yu-Ping, Z | 1 |
| Weng-Guang, L | 1 |
| Hua-Lei, L | 1 |
| Rurali, E | 1 |
| Noris, M | 1 |
| Chianca, A | 1 |
| Donadelli, R | 1 |
| Banterla, F | 1 |
| Galbusera, M | 1 |
| Gherardi, G | 1 |
| Gastoldi, S | 1 |
| Parvanova, A | 1 |
| Iliev, I | 1 |
| Bossi, A | 1 |
| Haefliger, C | 1 |
| Trevisan, R | 1 |
| Remuzzi, G | 1 |
| Ruggenenti, P | 1 |
| Kandadai, RM | 1 |
| Jabeen, SA | 1 |
| Kanikannan, MA | 1 |
| Borgohain, R | 1 |
| Chavarria, L | 1 |
| Romero-Giménez, J | 1 |
| Monteagudo, E | 1 |
| Lope-Piedrafita, S | 1 |
| Cordoba, J | 1 |
| Conde, VR | 1 |
| Oliveira, PF | 1 |
| Nunes, AR | 1 |
| Rocha, CS | 1 |
| Ramalhosa, E | 1 |
| Pereira, JA | 1 |
| Alves, MG | 1 |
| Silva, BM | 1 |
| Lupton, CJ | 1 |
| Steer, DL | 1 |
| Wintrode, PL | 1 |
| Bottomley, SP | 1 |
| Hughes, VA | 1 |
| Ellisdon, AM | 1 |
| Han, X | 1 |
| Jiang, K | 1 |
| Wang, B | 1 |
| Zhou, L | 1 |
| Chen, X | 1 |
| Li, S | 1 |
| Liu-Seifert, H | 1 |
| Siemers, E | 1 |
| Price, K | 1 |
| Han, B | 1 |
| Selzler, KJ | 1 |
| Henley, D | 1 |
| Sundell, K | 1 |
| Aisen, P | 1 |
| Cummings, J | 1 |
| Raskin, J | 1 |
| Mohs, R | 1 |
| Fabbri, M | 1 |
| Rosa, MM | 1 |
| Abreu, D | 1 |
| Ferreira, JJ | 1 |
| Yamasaki, T | 1 |
| Fujinaga, M | 1 |
| Kawamura, K | 1 |
| Furutsuka, K | 1 |
| Nengaki, N | 1 |
| Shimoda, Y | 1 |
| Shiomi, S | 1 |
| Takei, M | 1 |
| Hashimoto, H | 1 |
| Yui, J | 1 |
| Wakizaka, H | 1 |
| Hatori, A | 1 |
| Xie, L | 1 |
| Kumata, K | 1 |
| Zhang, MR | 1 |
| Milburn, J | 1 |
| Jones, R | 1 |
| Levy, JB | 1 |
| Kratter, IH | 1 |
| Zahed, H | 1 |
| Lau, A | 1 |
| Tsvetkov, AS | 1 |
| Daub, AC | 1 |
| Weiberth, KF | 1 |
| Gu, X | 1 |
| Saudou, F | 1 |
| Humbert, S | 1 |
| Yang, XW | 1 |
| Osmand, A | 1 |
| Steffan, JS | 1 |
| Masliah, E | 1 |
| Finkbeiner, S | 1 |
| Rönnbäck, A | 1 |
| Zhu, S | 1 |
| Dillner, K | 1 |
| Aoki, M | 1 |
| Lilius, L | 1 |
| Näslund, J | 1 |
| Winblad, B | 1 |
| Graff, C | 1 |
| D'Ambrosi, N | 1 |
| Finocchi, P | 1 |
| Apolloni, S | 1 |
| Cozzolino, M | 1 |
| Ferri, A | 1 |
| Padovano, V | 1 |
| Pietrini, G | 1 |
| Carrì, MT | 1 |
| Volonté, C | 1 |
| Sun, A | 1 |
| Paajanen, V | 1 |
| Wang, S | 3 |
| Su, C | 1 |
| Yang, Z | 1 |
| Li, Y | 2 |
| Jia, J | 1 |
| Wang, K | 2 |
| Zou, Y | 1 |
| Gao, L | 1 |
| Fan, Z | 1 |
| Schapira, AH | 1 |
| Bertea, M | 1 |
| Rütti, MF | 1 |
| Othman, A | 1 |
| Marti-Jaun, J | 1 |
| Hersberger, M | 1 |
| von Eckardstein, A | 1 |
| Hornemann, T | 1 |
| Yang, WW | 1 |
| Sidman, RL | 1 |
| Taksir, TV | 1 |
| Treleaven, CM | 1 |
| Fidler, JA | 1 |
| Cheng, SH | 1 |
| Dodge, JC | 1 |
| Shihabuddin, LS | 1 |
| Fujiwara, S | 1 |
| Morita, Y | 1 |
| Toyonaga, T | 1 |
| Kawakami, F | 1 |
| Itoh, T | 1 |
| Yoshida, M | 1 |
| Kutsumi, H | 1 |
| Azuma, T | 1 |
| Messadi, A | 1 |
| Fekih-Mrissa, N | 1 |
| Zaouali, J | 1 |
| Layouni, S | 1 |
| Nsiri, B | 1 |
| Yedeas, M | 1 |
| Raies, A | 1 |
| Mrissa, R | 1 |
| Gritli, N | 1 |
| Gravitz, L | 1 |
| Liang, H | 1 |
| Ward, WF | 1 |
| Jang, YC | 1 |
| Bhattacharya, A | 1 |
| Bokov, AF | 1 |
| Jernigan, A | 1 |
| Richardson, A | 1 |
| Van Remmen, H | 1 |
| Wang, X | 1 |
| Zhang, A | 1 |
| Han, Y | 1 |
| Wang, P | 1 |
| Sun, H | 1 |
| Song, G | 1 |
| Dong, T | 1 |
| Yuan, Y | 1 |
| Yuan, X | 1 |
| Zhang, M | 1 |
| Xie, N | 1 |
| Zhang, H | 1 |
| Dong, H | 1 |
| Dong, W | 1 |
| Squitieri, F | 1 |
| Cannella, M | 1 |
| Simonelli, M | 1 |
| Garbuzova-Davis, S | 1 |
| Willing, AE | 1 |
| Zigova, T | 1 |
| Saporta, S | 1 |
| Justen, EB | 1 |
| Lane, JC | 1 |
| Hudson, JE | 1 |
| Chen, N | 1 |
| Davis, CD | 1 |
| Sanberg, PR | 1 |
| Lynch, M | 1 |
| Fitzgerald, C | 1 |
| Johnston, KA | 1 |
| Schmidt, EV | 1 |
| Zhou, Q | 1 |
| Rammohan, K | 1 |
| Lin, S | 1 |
| Robinson, N | 1 |
| Li, O | 1 |
| Liu, X | 1 |
| Bai, XF | 1 |
| Yin, L | 1 |
| Scarberry, B | 1 |
| Du, P | 1 |
| You, M | 1 |
| Guan, K | 1 |
| Zheng, P | 1 |
| Liu, Y | 1 |
| Völkel, H | 1 |
| Selzle, M | 1 |
| Walk, T | 1 |
| Jung, G | 1 |
| Link, J | 1 |
| Ludolph, AC | 1 |
| Reuter, A | 1 |
| Giwercman, YL | 1 |
| Abrahamsson, PA | 1 |
| Giwercman, A | 1 |
| Gadaleanu, V | 1 |
| Ahlgren, G | 1 |
| Müller, T | 1 |
| Deschauer, M | 1 |
| Neudecker, S | 1 |
| Zierz, S | 1 |
| Stickel, F | 1 |
| Osterreicher, CH | 1 |
| Datz, C | 1 |
| Ferenci, P | 1 |
| Wölfel, M | 1 |
| Norgauer, W | 1 |
| Kraus, MR | 1 |
| Wrba, F | 1 |
| Hellerbrand, C | 1 |
| Schuppan, D | 1 |
| Mantuano, E | 1 |
| Veneziano, L | 1 |
| Al-Kateb, H | 1 |
| Boright, AP | 1 |
| Mirea, L | 1 |
| Xie, X | 1 |
| Sutradhar, R | 1 |
| Mowjoodi, A | 1 |
| Bharaj, B | 1 |
| Liu, M | 1 |
| Bucksa, JM | 1 |
| Arends, VL | 1 |
| Steffes, MW | 1 |
| Cleary, PA | 1 |
| Sun, W | 1 |
| Lachin, JM | 1 |
| Thorner, PS | 1 |
| Ho, M | 1 |
| McKnight, AJ | 1 |
| Maxwell, AP | 1 |
| Savage, DA | 1 |
| Kidd, KK | 1 |
| Kidd, JR | 1 |
| Speed, WC | 1 |
| Orchard, TJ | 1 |
| Miller, RG | 1 |
| Sun, L | 1 |
| Bull, SB | 1 |
| Paterson, AD | 1 |
| Casey, PA | 1 |
| McKenna, MC | 1 |
| Fiskum, G | 1 |
| Saraswati, M | 1 |
| Robertson, CL | 1 |
| Kawasaki, N | 1 |
| Lee, JD | 1 |
| Shimizu, H | 1 |
| Ishii, Y | 1 |
| Ueda, T | 1 |
| Furby, A | 1 |
| Mourtada, R | 1 |
| Charasse, C | 1 |
| Rivalan, J | 1 |
| Messner, M | 1 |
| Leroy, JP | 1 |
| Bink, H | 1 |
| Carbó, N | 1 |
| Felipe, A | 1 |
| López-Soriano, FJ | 1 |
| Argilés, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of COVID-19 in an Outpatient Setting[NCT04501952] | Phase 3 | 584 participants (Actual) | Interventional | 2020-09-18 | Terminated (stopped due to The study was terminated due to study enrollment feasibility and changing needs of non-hospitalized participants. This decision is not based on efficacy or safety concerns.) | ||
| A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment[NCT04292730] | Phase 3 | 1,113 participants (Actual) | Interventional | 2020-03-15 | Completed | ||
| A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Severe COVID-19.[NCT04257656] | Phase 3 | 237 participants (Actual) | Interventional | 2020-02-06 | Terminated (stopped due to The epidemic of COVID-19 has been controlled well in China, no eligible patients can be enrolled at present.) | ||
| A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Mild and Moderate COVID-19.[NCT04252664] | Phase 3 | 308 participants (Anticipated) | Interventional | 2020-02-12 | Suspended (stopped due to The epidemic of COVID-19 has been controlled well at present, no eligible patients can be recruitted.) | ||
| "WHO Public Health Emergency Solidarity Clinical Trial for COVID-19 Treatments"[NCT04647669] | Phase 3 | 100 participants (Anticipated) | Interventional | 2021-06-01 | Not yet recruiting | ||
| Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19): An Open Label, Multi-Center, Randomized Controlled Trial[NCT04596839] | Phase 2 | 60 participants (Actual) | Interventional | 2020-09-04 | Completed | ||
| The (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected Patients[NCT04321616] | Phase 2/Phase 3 | 700 participants (Anticipated) | Interventional | 2020-03-28 | Recruiting | ||
| A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults[NCT04280705] | Phase 3 | 1,062 participants (Actual) | Interventional | 2020-02-21 | Completed | ||
| A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With th[NCT04330690] | Phase 3 | 2,900 participants (Anticipated) | Interventional | 2020-03-18 | Active, not recruiting | ||
| Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults[NCT04315948] | Phase 3 | 1,552 participants (Actual) | Interventional | 2020-03-22 | Completed | ||
| Phase II Study to Evaluate Immunogenicity and Safety in Subjects With Evidence of Prior Immunity to SARS-CoV-2 of a Single Intramuscular or Intranasal Dose of the Live Recombinant Newcastle Disease Virus Based AVX/COVID-12 Vaccine[NCT05205746] | Phase 2 | 158 participants (Actual) | Interventional | 2021-11-23 | Completed | ||
| Phase II/III Parallel, Double-blind, Non-inferiority Study With Active Control, to Evaluate the Immunogenicity and Safety of a Booster Immunization Scheme With a Single Intramuscular Dose of the Recombinant Vaccine Against SARS-CoV-2[NCT05710783] | Phase 2/Phase 3 | 4,065 participants (Actual) | Interventional | 2022-11-09 | Completed | ||
| A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)[NCT01267253] | Phase 2 | 31 participants (Actual) | Interventional | 2011-04-04 | Completed | ||
| Exhaled Breath Analysis by Secondary Electrospray Ionization - Mass Spectrometry (SESI-MS) in Patients With Pulmonary Fibrosis[NCT02437448] | 31 participants (Actual) | Observational | 2015-06-30 | Completed | |||
| A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT)[NCT00235014] | Phase 4 | 1,204 participants (Actual) | Interventional | 1997-03-31 | Completed | ||
| Effect of γ-Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 Versus Placebo[NCT00594568] | Phase 3 | 1,537 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Effect of LY450139 a y-Secretase Inhibitor, on the Progression of Alzheimer's Disease as Compared With Placebo[NCT00762411] | Phase 3 | 1,111 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Effect of LY2062430, an Anti-Amyloid Beta Monoclonal Antibody, on the Progression of Alzheimer's Disease as Compared With Placebo[NCT00905372] | Phase 3 | 1,000 participants (Anticipated) | Interventional | 2009-05-31 | Completed | ||
| Effect of Passive Immunization on the Progression of Alzheimer's Disease: LY2062430 Versus Placebo[NCT00904683] | Phase 3 | 1,040 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT04501952)
Timeframe: Randomization up to Day 28
| Intervention | percentage of participants (Number) |
|---|---|
| Remdesivir | 0 |
| Placebo | 0 |
TEAEs were defined as any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or any AEs leading to premature discontinuation of study drug. (NCT04501952)
Timeframe: First dose date up to last dose date (maximum: 3 days) plus 30 days
| Intervention | percentage of participants (Number) |
|---|---|
| Remdesivir | 42.3 |
| Placebo | 46.3 |
(NCT04501952)
Timeframe: Randomization up to Day 28
| Intervention | percentage of participants (Number) |
|---|---|
| Remdesivir | 0.4 |
| Placebo | 1.8 |
The composite outcome of COVID-19 related hospitalization (defined as at least 24 hours of acute care) or all-cause death by Day 28 was derived by combining the available all-cause death and COVID-19 related hospitalization reported by the site. The first COVID-19 related hospitalization was used for the percentage of COVID-19 related hospitalization or all-cause death. The percentage of the composite outcome was from the Kaplan-Meier estimate. (NCT04501952)
Timeframe: Randomization up to Day 28
| Intervention | percentage of participants (Number) |
|---|---|
| Remdesivir | 0.7 |
| Placebo | 5.4 |
COVID-19 related hospitalization is defined as at least 24 hours of acute care derived by COVID-19 related hospitalization reported by the site. The percentage of the outcome and the corresponding 95% confidence interval were from Kaplan-Meier estimate. (NCT04501952)
Timeframe: Randomization up to Day 28
| Intervention | percentage of participants (Number) |
|---|---|
| Remdesivir | 0.7 |
| Placebo | 5.4 |
The composite outcome of COVID-19 related hospitalization (defined as at least 24 hours of acute care) or all-cause death by Day 14 was derived by combining the available all-cause death and COVID-19 related hospitalization reported by the site. The first COVID-19 related hospitalization was used for the percentage of COVID-19 related hospitalization or all-cause death. The percentage of the composite outcome was from the Kaplan-Meier estimate. (NCT04501952)
Timeframe: Randomization up to Day 14
| Intervention | percentage of participants (Number) |
|---|---|
| Remdesivir | 0.7 |
| Placebo | 5.4 |
The composite outcome of COVID-19 related MAVs or all-cause death by Day 14 was derived by combining the available all-cause death and COVID-19 related MAVs reported by the site. The percentage of the composite outcome was from the Kaplan-Meier estimate. (NCT04501952)
Timeframe: Randomization up to Day 14
| Intervention | percentage of participants (Number) |
|---|---|
| Remdesivir | 0.8 |
| Placebo | 8.0 |
The composite outcome of COVID-19 related MAVs or all-cause death by Day 28 was derived by combining the available all-cause death and COVID-19 related MAVs reported by the site. The percentage of the composite outcome was from the Kaplan-Meier estimate. (NCT04501952)
Timeframe: Randomization up to Day 28
| Intervention | percentage of participants (Number) |
|---|---|
| Remdesivir | 1.7 |
| Placebo | 8.5 |
The worsening after alleviation of baseline COVID-19 symptoms is defined as for a participant who has achieved alleviation of baseline COVID-19 symptoms, if symptom scored as 2 or higher at baseline is scored as 2 or higher postbaseline after achieved alleviation, or symptoms scored as 1 at baseline are scored as 1 or higher postbaseline after achieved alleviation. The COVID-19-adapted FLU-PRO Plus was used. It is a questionnaire that assesses the severity of symptoms in participants with COVID-19 across six body systems: nose, throat, eyes, chest/respiratory, gastrointestinal, and body/systemic. Each domain scores range from 0 (symptom free) to 4 (very severe symptoms). A higher score indicates increased symptom severity. Alleviation is defined as symptom scores of 0 (absent) or 1 (mild). (NCT04501952)
Timeframe: First dose date up to Day 28
| Intervention | percentage of participants (Number) |
|---|---|
| Remdesivir | 30.4 |
| Placebo | 13.3 |
The COVID-19-adapted FLU-PRO Plus is a questionnaire that assesses the severity of symptoms in participants with COVID-19 across six body systems: nose, throat, eyes, chest/respiratory, gastrointestinal, and body/systemic. Each domain scores range from 0 (symptom free) to 4 (very severe symptoms). A higher score indicates increased symptom severity. Alleviation is defined as symptom scores of 0 (absent) or 1 (mild). Time to alleviation of baseline COVID-19 symptoms is defined (in days) as: First Date of the two consecutive dates achieving alleviation - First dose Date + 1. If a participant had not achieved symptom alleviation at last FLU-PRO Plus assessment or early discontinuation of study, the participant was censored at last FLU-PRO Plus assessment date. (NCT04501952)
Timeframe: First Dose Date up to Day 14
| Intervention | days (Median) |
|---|---|
| Remdesivir | NA |
| Placebo | NA |
The time-weighted average change from baseline to study Day 7 (DAVG7) in SARS-CoV-2 viral load is defined as the time-weighted average between the first postbaseline value through the last available value up to Day 7 minus the baseline value in SARS-CoV-2 viral load (log10 copies/mL). DAVG7 is calculated using the trapezoidal rule and the area under the curve (AUC). For participants with data through days prior to Day 7, the time-weighted average change used data up to last available timepoint. If there was no postbaseline data, the participant was excluded from the analysis. (NCT04501952)
Timeframe: Baseline up to Day 7
| Intervention | log10 copies/ mililiter (mL) (Mean) |
|---|---|
| Remdesivir | -1.24 |
| Placebo | -1.14 |
TEAEs were defined as the following: any AE with an onset date on or after the study treatment start date and no later than 30 days after permanent discontinuation of study treatment and/or any AE leading to premature discontinuation of study treatment. For participants randomized to the SOC group, all AEs reported on or after the protocol-specified Day 1 visit were considered as treatment emergent. (NCT04292730)
Timeframe: First dose date up to last dose date (maximum: 10 days) plus 30 days
| Intervention | percentage of participants (Number) |
|---|---|
| Part A: Remdesivir for 5 Days | 51.3 |
| Part A: Remdesivir for 10 Days | 58.5 |
| Part A: SOC Therapy | 46.5 |
"Clinical status was derived from death, hospital discharge, and ordinal scale as follows: score of 1 was used for all days on or after the date of death; score of 7 was used for all days on or after discharged alive date; last available assessment for missing value. The scale is as follows: 1. Death; 2. Hospitalized, on invasive mechanical ventilation or Extracorporeal Membrane Oxygenation (ECMO); 3. Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring low flow supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (coronavirus (COVID-19) related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care (other than per protocol remdesivir administration; 7. Not hospitalized. The odds ratio represents the odds of improvement in the ordinal scale for a RDV group relative to the SOC group." (NCT04292730)
Timeframe: Day 11
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Score: 1 | Score: 2 | Score: 3 | Score: 4 | Score: 5 | Score: 6 | Score: 7 | |
| Part A: Remdesivir for 10 Days | 1.0 | 0.5 | 0.0 | 6.2 | 22.8 | 4.7 | 64.8 |
| Part A: Remdesivir for 5 Days | 0.0 | 0.0 | 2.6 | 3.7 | 19.9 | 3.7 | 70.2 |
| Part A: SOC Therapy | 2.0 | 2.0 | 3.5 | 5.5 | 23.0 | 4.0 | 60.0 |
The mortality rate was determined as the proportion of participants who died by study Day 15. (NCT04280705)
Timeframe: Day 1 through Day 15
| Intervention | Proportion of participants (Number) |
|---|---|
| Placebo | 0.12 |
| Remdesivir | 0.07 |
The mortality rate was determined as the proportion of participants who died by study Day 29. (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | Proportion of participants (Number) |
|---|---|
| Placebo | 0.15 |
| Remdesivir | 0.11 |
Grade 3 AEs are defined as events that interrupt usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Severe events are usually incapacitating. Grade 4 AEs are defined as events that are potentially life threatening. (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 57 |
| Remdesivir | 51 |
An SAE is defined as an AE or suspected adverse reaction is considered serious if, in the view of either the investigator or the sponsor, it results in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect. (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 32 |
| Remdesivir | 24 |
New non-invasive ventilation or high-flow oxygen use was determined as the percentage of subject not on non-invasive ventilation or high-flow oxygen at baseline. (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 24 |
| Remdesivir | 17 |
The percentage of participants requiring new oxygen use was determined as the percentage of participants not requiring oxygen at baseline (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 44 |
| Remdesivir | 36 |
The percentage of participants requiring new ventilator or ECMO use was determined as the percentage not on a ventilator or ECMO at baseline (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 23 |
| Remdesivir | 13 |
The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities. Time to improvement by at least one category was determined for each participant (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | Days (Median) |
|---|---|
| Placebo | 9 |
| Remdesivir | 7 |
The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities. Time to improvement by at least two categories was determined for each participant (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | Days (Median) |
|---|---|
| Placebo | 14 |
| Remdesivir | 11 |
The NEW score has demonstrated an ability to discriminate patients at risk of poor outcomes. This score is based on 7 clinical parameters (respiration rate, oxygen saturation, any supplemental oxygen, temperature, systolic blood pressure, heart rate, level of consciousness). The NEW Score is being used as an efficacy measure. The minimum score is 0, representing the better outcome, and the maximum value is 19, representing the worse outcome. The time to discharge or a NEWS of less than or equal to 2 was determined for each participant. (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | Days (Median) |
|---|---|
| Placebo | 12 |
| Remdesivir | 8 |
Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the ordinal scale: 1) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Not hospitalized, no limitations on activities. (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | Days (Median) |
|---|---|
| Placebo | 15 |
| Remdesivir | 10 |
Blood to evaluate ALT was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15 and 29
| Intervention | Units/Liter (U/L) (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 29 | |
| Placebo | 14.3 | 23.1 | 24.2 | 27.7 | 28.1 | -3.9 |
| Remdesivir | 2.9 | 10.8 | 8.9 | 3.4 | 1.7 | -6.8 |
Blood to evaluate AST was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15 and 29
| Intervention | Units/Liter (U/L) (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 29 | |
| Placebo | 13.7 | 12.8 | 13.1 | 11.5 | 4.2 | -18.4 |
| Remdesivir | -2.0 | 6.0 | 1.1 | -0.3 | -2.3 | -14.0 |
Blood to evaluate basophils was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15 and 29
| Intervention | 10^9 cells/liter (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 29 | |
| Placebo | 0.020 | 0.038 | 0.196 | 0.024 | 0.158 | 0.040 |
| Remdesivir | 0.005 | 0.005 | 0.005 | 0.028 | -0.058 | 0.029 |
Blood to evaluate serum creatinine was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15 and 29
| Intervention | milligrams/deciliter (mg/dL) (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 29 | |
| Placebo | 0.037 | -0.695 | -0.882 | 1.173 | -1.239 | -1.863 |
| Remdesivir | 0.038 | 0.075 | 0.158 | 0.236 | 0.319 | 0.075 |
Blood to evaluate eosinophils was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15 and 29
| Intervention | 10^9 cells/liter (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 29 | |
| Placebo | 0.634 | 0.666 | 0.596 | 0.093 | 1.992 | 0.241 |
| Remdesivir | 0.016 | -0.066 | -0.221 | -0.088 | -0.420 | 0.211 |
Blood to evaluate serum glucose was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15 and 29
| Intervention | mg/dL (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 29 | |
| Placebo | -0.2 | 6.3 | 2.2 | 1.0 | -2.8 | -13.5 |
| Remdesivir | -3.0 | 2.1 | 3.2 | -0.1 | -2.9 | -11.7 |
Blood to evaluate hemoglobin was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15 and 29
| Intervention | grams/deciliter (g/dL) (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 29 | |
| Placebo | -0.52 | -0.83 | -1.22 | -1.66 | -1.51 | -1.02 |
| Remdesivir | -0.69 | -0.99 | -0.49 | -1.29 | -1.02 | -1.21 |
Blood to evaluate lymphocytes was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15 and 29
| Intervention | 10^9 cells/liter (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 29 | |
| Placebo | 5.883 | 4.064 | 8.006 | 0.393 | 14.793 | 0.668 |
| Remdesivir | -7.847 | -11.723 | -15.455 | -12.016 | -23.836 | 0.743 |
Blood to evaluate monocytes was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15 and 29
| Intervention | 10^9 cells/liter (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 29 | |
| Placebo | 2.448 | 1.498 | 2.324 | 0.383 | 6.475 | 0.125 |
| Remdesivir | -2.940 | -2.628 | -3.645 | -2.539 | -8.738 | 0.117 |
Blood to evaluate neutrophils was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15 and 29
| Intervention | 10^9 cells/liter (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 29 | |
| Placebo | 9.429 | 4.177 | 17.916 | 3.010 | 36.024 | -1.269 |
| Remdesivir | -8.093 | -15.067 | -28.179 | -21.773 | -39.988 | -0.840 |
Blood to evaluate platelets was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15 and 29
| Intervention | 10^9 cells/liter (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 29 | |
| Placebo | 39.3 | 76.5 | 111.8 | 109.3 | 96.5 | 32.7 |
| Remdesivir | 46.0 | 90.1 | 130.8 | 101.0 | 71.1 | 39.6 |
Blood to evaluate PT was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15 and 29
| Intervention | seconds (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 29 | |
| Placebo | -0.18 | -0.30 | 0.01 | 0.86 | 0.34 | -0.28 |
| Remdesivir | 0.44 | 1.15 | 1.43 | 1.88 | -0.03 | -0.63 |
Blood to evaluate total bilirubin was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15 and 29
| Intervention | mg/dL (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 29 | |
| Placebo | 0.08 | 0.58 | 0.22 | 0.23 | 0.00 | -0.17 |
| Remdesivir | -0.04 | -0.03 | 0.01 | 0.07 | 0.09 | -0.12 |
Blood to evaluate WBC was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15 and 29
| Intervention | 10^9 cells/liter (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 29 | |
| Placebo | 18.691 | 9.886 | 27.223 | 1.967 | 56.311 | -0.898 |
| Remdesivir | -18.970 | -28.209 | -45.997 | -34.702 | -70.884 | 0.251 |
The NEW score has demonstrated an ability to discriminate patients at risk of poor outcomes. This score is based on 7 clinical parameters (respiration rate, oxygen saturation, any supplemental oxygen, temperature, systolic blood pressure, heart rate, level of consciousness). The NEW Score is being used as an efficacy measure. The minimum score is 0, representing the better outcome, and the maximum value is 19, representing the worse outcome. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15, 22, and 29
| Intervention | units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 22 | Day 29 | |
| Placebo | 0.1 | 0.3 | -0.3 | -0.3 | -1.4 | -1.4 | -3.2 |
| Remdesivir | -0.3 | -0.4 | -0.5 | -0.5 | -1.7 | -1.7 | -3.3 |
Duration of hospitalization was determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die. (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | Days (Median) | |
|---|---|---|
| Including imputation for participants who died | Restricted to participants who did not die | |
| Placebo | 17 | 14 |
| Remdesivir | 12 | 10 |
Duration of new non-invasive ventilation or high flow oxygen use was measured in days among participants who were not on non-invasive ventilation or high-flow oxygen use at baseline, determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | Days (Median) | |
|---|---|---|
| Including imputations for participants who died | Among participants who did not die | |
| Placebo | 4 | 3 |
| Remdesivir | 3 | 3 |
"Duration of new oxygen use was measured in days among participants who were not on oxygen at baseline, determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die~." (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | Days (Median) | |
|---|---|---|
| Including imputations for participants who died | Among participants who did not die | |
| Placebo | 5.5 | 3 |
| Remdesivir | 4 | 3.5 |
Duration of new ventilator or ECMO use was measured in days among participants who were not on a ventilator or ECMO at baseline, determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | Days (Median) | |
|---|---|---|
| Including imputations for participants who died | Among participants who did not die | |
| Placebo | 23 | 16 |
| Remdesivir | 21.5 | 14 |
The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities. A positive change indicates a worsening and a negative change is an improvement. (NCT04280705)
Timeframe: Day 1, 3, 5, 8, 11, 15, 22, and 29
| Intervention | units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 22 | Day 29 | |
| Placebo | 0.2 | 0.1 | 0.0 | -0.1 | -1.4 | -1.9 | -2.3 |
| Remdesivir | 0.1 | 0.0 | -0.2 | -0.3 | -1.9 | -2.4 | -2.7 |
The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities. (NCT04280705)
Timeframe: Day 1
| Intervention | percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Death at or before study Visit | Hospitalized, on invasive mech. vent. or ECMO | Hospitalized, on non-invasive vent./high flow O2 | Hospitalized, requiring supplemental oxygen | Hospitalized, not on O2, requiring ongoing care | Hospitalized, not requiring O2, no longer req care | Not hospitalized, limit on activities/req home O2 | Not hospitalized, no limitations on activities | No clinical status score reported - Hospitalized | No clinical status score reported - Discharged | No clinical status score reported - Discontinued | |
| Placebo | 0 | 30 | 19 | 39 | 12 | 0 | 0 | 0 | 0 | 0 | 1 |
| Remdesivir | 0 | 24 | 18 | 43 | 14 | 0 | 0 | 0 | 1 | 0 | 1 |
The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities. (NCT04280705)
Timeframe: Day 11
| Intervention | percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Death at or before study Visit | Hospitalized, on invasive mech. vent. or ECMO | Hospitalized, on non-invasive vent./high flow O2 | Hospitalized, requiring supplemental oxygen | Hospitalized, not on O2, requiring ongoing care | Hospitalized, not requiring O2, no longer req care | Not hospitalized, limit on activities/req home O2 | Not hospitalized, no limitations on activities | No clinical status score reported - Hospitalized | No clinical status score reported - Discharged | No clinical status score reported - Discontinued | |
| Placebo | 8 | 28 | 7 | 13 | 6 | 2 | 0.4 | 0.2 | 0 | 33 | 2 |
| Remdesivir | 4 | 22 | 6 | 11 | 7 | 2 | 0.4 | 0 | 0 | 44 | 4 |
The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities. (NCT04280705)
Timeframe: Day 15
| Intervention | percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Death at or before study Visit | Hospitalized, on invasive mech. vent. or ECMO | Hospitalized, on non-invasive vent./high flow O2 | Hospitalized, requiring supplemental oxygen | Hospitalized, not on O2, requiring ongoing care | Hospitalized, not requiring O2, no longer req care | Not hospitalized, limit on activities/req home O2 | Not hospitalized, no limitations on activities | No clinical status score reported - Hospitalized | No clinical status score reported - Discharged | No clinical status score reported - Discontinued | |
| Placebo | 11 | 22 | 4 | 11 | 6 | 2 | 17 | 22 | 0 | 2 | 3 |
| Remdesivir | 6 | 15 | 4 | 10 | 7 | 3 | 19 | 29 | 0 | 2 | 5 |
The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities. (NCT04280705)
Timeframe: Day 22
| Intervention | percentage of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Death at or before study Visit | Hospitalized, on invasive mech. vent. or ECMO | Hospitalized, on non-invasive vent./high flow O2 | Hospitalized, requiring supplemental oxygen | Hospitalized, not on O2, requiring ongoing care | Hospitalized, not requiring O2, no longer req care | Not hospitalized, limit on activities/req home O2 | Not hospitalized, no limitations on activities | No clinical status score reported - Hospitalized | No clinical status score reported - Discharged | No clinical status score reported - Discontinued | Completed study without reporting score | |
| Placebo | 13 | 14 | 2 | 8 | 5 | 1 | 18 | 32 | 0 | 2 | 4 | 0 |
| Remdesivir | 9 | 9 | 2 | 5 | 6 | 1 | 19 | 39 | 0 | 3 | 6 | 0.2 |
The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities. (NCT04280705)
Timeframe: Day 29
| Intervention | percentage of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Death at or before study Visit | Hospitalized, on invasive mech. vent. or ECMO | Hospitalized, on non-invasive vent./high flow O2 | Hospitalized, requiring supplemental oxygen | Hospitalized, not on O2, requiring ongoing care | Hospitalized, not requiring O2, no longer req care | Not hospitalized, limit on activities/req home O2 | Not hospitalized, no limitations on activities | No clinical status score reported - Hospitalized | No clinical status score reported - Discharged | No clinical status score reported - Discontinued | Completed study without reporting score | |
| Placebo | 15 | 9 | 2 | 4 | 3 | 1 | 19 | 36 | 0.2 | 3 | 5 | 3 |
| Remdesivir | 11 | 6 | 1 | 4 | 3 | 1 | 20 | 46 | 0 | 1 | 7 | 2 |
The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities. (NCT04280705)
Timeframe: Day 3
| Intervention | percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Death at or before study Visit | Hospitalized, on invasive mech. vent. or ECMO | Hospitalized, on non-invasive vent./high flow O2 | Hospitalized, requiring supplemental oxygen | Hospitalized, not on O2, requiring ongoing care | Hospitalized, not requiring O2, no longer req care | Not hospitalized, limit on activities/req home O2 | Not hospitalized, no limitations on activities | No clinical status score reported - Hospitalized | No clinical status score reported - Discharged | No clinical status score reported - Discontinued | |
| Placebo | 1 | 36 | 17 | 32 | 12 | 0.4 | 0 | 0 | 0 | 0.2 | 1 |
| Remdesivir | 1 | 28 | 16 | 37 | 13 | 0.2 | 0 | 0.4 | 0 | 2 | 2 |
The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities. (NCT04280705)
Timeframe: Day 5
| Intervention | percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Death at or before study Visit | Hospitalized, on invasive mech. vent. or ECMO | Hospitalized, on non-invasive vent./high flow O2 | Hospitalized, requiring supplemental oxygen | Hospitalized, not on O2, requiring ongoing care | Hospitalized, not requiring O2, no longer req care | Not hospitalized, limit on activities/req home O2 | Not hospitalized, no limitations on activities | No clinical status score reported - Hospitalized | No clinical status score reported - Discharged | No clinical status score reported - Discontinued | |
| Placebo | 2 | 37 | 14 | 26 | 11 | 1 | 0 | 0.2 | 0 | 7 | 2 |
| Remdesivir | 2 | 28 | 12 | 28 | 15 | 1 | 0.2 | 0 | 0 | 12 | 3 |
The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities. (NCT04280705)
Timeframe: Day 8
| Intervention | percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Death at or before study Visit | Hospitalized, on invasive mech. vent. or ECMO | Hospitalized, on non-invasive vent./high flow O2 | Hospitalized, requiring supplemental oxygen | Hospitalized, not on O2, requiring ongoing care | Hospitalized, not requiring O2, no longer req care | Not hospitalized, limit on activities/req home O2 | Not hospitalized, no limitations on activities | No clinical status score reported - Hospitalized | No clinical status score reported - Discharged | No clinical status score reported - Discontinued | |
| Placebo | 7 | 33 | 9 | 15 | 10 | 1 | 0 | 0.2 | 0 | 22 | 2 |
| Remdesivir | 3 | 24 | 9 | 17 | 11 | 1 | 0.2 | 0 | 0.4 | 30 | 4 |
Participants may have been discontinued from investigational therapeutics due to discharge or death. The halting or slowing of the infusion for any reason was collected, as was missed doses in the series of 10 doses. (NCT04280705)
Timeframe: Day 1 through Day 10
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Discontinued due to discharge | Discontinued due to death | Any infusions halted or slowed | Missed any maintenance dose | |
| Placebo | 30 | 4 | 2 | 21 |
| Remdesivir | 41 | 3 | 2 | 16 |
Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the ordinal scale: 1) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Not hospitalized, no limitations on activities. (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | Days (Median) | |
|---|---|---|
| Not Hispanic or Latino | Hispanic or Latino | |
| Placebo | 15.0 | 12.5 |
| Remdesivir | 10.0 | 10.0 |
Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the ordinal scale: 1) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Not hospitalized, no limitations on activities. (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | Days (Median) | |||
|---|---|---|---|---|
| Asian | Black or African American | White | Other | |
| Placebo | 12.0 | 15.0 | 15.0 | 24.0 |
| Remdesivir | 11.0 | 10.0 | 9.0 | 9.0 |
Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the ordinal scale: 1) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Not hospitalized, no limitations on activities. (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | Days (Median) | |
|---|---|---|
| Male | Female | |
| Placebo | 15.0 | 15.0 |
| Remdesivir | 9.0 | 10.0 |
Proportion of participants with objective tumor response. Objective tumor response is defined as complete or partial tumor response assessed by RECIST 1.1 (NCT01267253)
Timeframe: Every other cycle for first 6 months; then every 3 months thereafter until disease progression confirmed; and at any other time if clinically indicated based on symptoms or physical signs suggestive of progressive disease.
| Intervention | proportion (Number) |
|---|---|
| Brivanib | 0.071 |
Overall survival is defined as the duration of time from study entry to time of death or the date of last contact.. (NCT01267253)
Timeframe: From study entry to time of death or the date of last contact, up to 5 years of follow-up.
| Intervention | Months (Median) |
|---|---|
| Brivanib | 7.9 |
Proportion of participants who survive progression-free for at least 6 months without non-protocol therapy from study entry. Progression is assessed by RECIST 1.1. (NCT01267253)
Timeframe: Every other cycle for first 6 months; then every 3 months therafter until disease progression confirmed; and at any other time if cliniclly indicated based on symptoms or physical signs suggestive of progressive disease
| Intervention | proportion (Number) |
|---|---|
| Brivanib | 0.179 |
Progression-free survival is the period of time from study entry to time of disease progression, death or date of last contact, whichever occurs first. Progression is assessed by RECIST 1.1 (NCT01267253)
Timeframe: From study entry to time of progression or death, whichever occurs first, up to 5 years of follow-up
| Intervention | Months (Median) |
|---|---|
| Brivanib | 3.2 |
Number of participants with a maximum grade of 3 or higher during treatment period. Adverse events are graded and categorized using CTCAE v.4.0 (NCT01267253)
Timeframe: During treatment period and up to 30 days after stopping the study treatment.
| Intervention | Participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leukopenia | Thrombocytopenia | Neutropenia | Anemia | Other Investigations | Cardiac Disorders | Gastrointestinal Disorders | General disorders & administration site conditions | Hepatobiliary Disorders | Infections and infestations | Metabolism and nutrition disorders | Musculoskeletal & connective tissue disorders | Neoplasms benign, malignant & unspecified | Nervous system disorders | Renal and urinary disorders | Vascular Disorders | |
| Brivanib | 0 | 0 | 0 | 4 | 4 | 1 | 7 | 2 | 1 | 4 | 5 | 3 | 2 | 3 | 2 | 5 |
ADAS-Cog11 consists of 11 items assessing areas of function most typically impaired in Alzheimer's disease (AD): orientation, verbal memory, language, and praxis. The scale ranges from 0 to 70, with higher scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00594568)
Timeframe: Baseline (randomization), 16 weeks following treatment cessation
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 6.59 |
| 100 mg LY450139 | 7.57 |
| 140 mg LY450139 | 7.90 |
ADAS-Cog11 was used as a primary efficacy measure. It consists of 11 items assessing areas of function most typically impaired in Alzheimer's disease (AD): orientation, verbal memory, language, and praxis. The scale ranges from 0 to 70, with higher scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00594568)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 6.19 |
| 100 mg LY450139 | 7.29 |
| 140 mg LY450139 | 7.68 |
ADAS-Cog12 is ADAS-Cog11 augmented with delayed free recall measure, resulting in a total score ranging from 0 to 80. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00594568)
Timeframe: Baseline (randomization), 16 weeks following treatment cessation
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 6.97 |
| 100 mg LY450139 | 8.27 |
| 140 mg LY450139 | 8.41 |
ADAS-Cog12 is ADAS-Cog11 augmented with delayed free recall measure, resulting in a total score ranging from 0 to 80. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00594568)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 6.52 |
| 100 mg LY450139 | 7.98 |
| 140 mg LY450139 | 8.33 |
ADAS-Cog14 is ADAS-Cog11 augmented with delayed free recall, digit cancellation, and maze completion measures. A score of 0 to 10 for delayed free recall and a conversion code of 0 to 5 for digit cancellation and maze completion provide total score ranges for this extended ADAS-Cog14 of 0 to 90. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, concomitant standard of care (SOC) medication. (NCT00594568)
Timeframe: Baseline (randomization), 16 weeks following treatment cessation
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 7.90 |
| 100 mg LY450139 | 9.30 |
| 140 mg LY450139 | 9.89 |
ADAS-Cog14 is ADAS-Cog11 augmented with delayed free recall, digit cancellation, and maze completion measures. A score of 0 to 10 for delayed free recall and a conversion code of 0 to 5 for digit cancellation and maze completion provide total score ranges for this extended ADAS-Cog14 of 0 to 90. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, concomitant standard of care (SOC) medication. (NCT00594568)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 7.42 |
| 100 mg LY450139 | 8.97 |
| 140 mg LY450139 | 9.48 |
ADCS-ADL is a 23-item inventory developed as a Rater-administered questionnaire answered by the participant's caregiver. It measures performance of basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00594568)
Timeframe: Baseline (randomization), 16 weeks following treatment cessation
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -9.26 |
| 100 mg LY450139 | -9.15 |
| 140 mg LY450139 | -11.73 |
ADCS-ADL is a 23-item inventory developed as a Rater-administered questionnaire answered by the participant's caregiver. It measures performance of basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00594568)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -8.76 |
| 100 mg LY450139 | -10.13 |
| 140 mg LY450139 | -12.70 |
Concentration of an amino peptide known as Aβ 1-42 in spinal fluid. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator. (NCT00594568)
Timeframe: Baseline (randomization), up to 76 weeks
| Intervention | picogram per milliliter (pg/mL) (Least Squares Mean) |
|---|---|
| Placebo | -86.16 |
| 100 mg LY450139 | 23.27 |
| 140 mg LY450139 | -40.51 |
A radioactive tracer for PET that is a ligand for amyloid called AV-45. This permits the visualization of amyloid in the brains of Alzheimer's participants. The outcome reported is the composite summary of the standard uptake value ratio (SUVR) normalized to the cerebellar gray matter. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator. (NCT00594568)
Timeframe: Baseline (randomization), up to 76 weeks
| Intervention | ratio (Least Squares Mean) |
|---|---|
| Placebo | 0.08 |
| 100 mg LY450139 | 0.06 |
| 140 mg LY450139 | 0.09 |
CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00594568)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 2.31 |
| 100 mg LY450139 | 2.73 |
| 140 mg LY450139 | 3.04 |
EQ-5D (proxy version) measures mobility, self-care, usual activities, pain/discomfort, anxiety/depression; each has 3 severity levels (no, some, severe problems) coded to a 1-digit number (1-3). Digits are combined into 5-digit number describing health state. Numerals 1-3 are not added for total score. VAS assesses caregiver's impression of participant's overall health state; scores range from 0 to 100; Lower scores indicate greater disease severity. Least Squares (LS) Mean value controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00594568)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -1.41 |
| 100 mg LY450139 | -7.49 |
| 140 mg LY450139 | -5.33 |
MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, and ability to name objects, follow verbal and written commands, write a sentence, and copy figures) in elderly participants. The total score ranges from 0 to 30; Lower score indicates greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00594568)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -2.95 |
| 100 mg LY450139 | -3.14 |
| 140 mg LY450139 | -3.71 |
NPI assesses psychopathology in participants with dementia and other neurologic disorders. Information is obtained from a caregiver familiar with the participant's behavior. Total score ranges from 12 to 144; Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00594568)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 1.92 |
| 100 mg LY450139 | 3.31 |
| 140 mg LY450139 | 4.15 |
Concentration of p-tau in spinal fluid. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator. (NCT00594568)
Timeframe: Baseline (randomization), up to 76 weeks
| Intervention | picogram per milliliter (pg/mL) (Least Squares Mean) |
|---|---|
| Placebo | 9.75 |
| 100 mg LY450139 | -6.26 |
| 140 mg LY450139 | -5.13 |
Measurement of local cerebral glucose metabolism by PET using the radioactive tracer 18F-FDG. The outcome reported is the composite summary of the standard uptake value ratio (SUVR) normalized to the Pons. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator. (NCT00594568)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | ratio (Least Squares Mean) |
|---|---|
| Placebo | -0.08 |
| 100 mg LY450139 | -0.12 |
| 140 mg LY450139 | -0.11 |
Assesses healthcare resource utilization (formal and informal care). Information gathered on both caregivers (caregiving time, work status) and participants (accommodation and healthcare resource utilization) was collected from baseline and follow-up interviews; Reported number of hospitalizations per participant up to 76 weeks. Least Squares (LS) Mean value was controlled for age and investigator. (NCT00594568)
Timeframe: Baseline (randomization), up to 76 weeks
| Intervention | hospitalizations/participant (Least Squares Mean) |
|---|---|
| Placebo | 0.55 |
| 100 mg LY450139 | 0.66 |
| 140 mg LY450139 | 0.83 |
Concentration of total tau in spinal fluid. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator. (NCT00594568)
Timeframe: Baseline (randomization), up to 76 weeks
| Intervention | picogram per milliliter (pg/mL) (Least Squares Mean) |
|---|---|
| Placebo | 75.11 |
| 100 mg LY450139 | 20.50 |
| 140 mg LY450139 | 61.00 |
Model estimated apparent oral clearance. Clearance is defined as the volume of plasma that is completely cleared of drug (LY450139) per unit time. (NCT00594568)
Timeframe: 6 weeks, 12 weeks, and 52 weeks
| Intervention | liter per hour (L/h) (Geometric Mean) |
|---|---|
| LY450139 | 18.8 |
Model-estimated apparent volume of distribution. Volume of distribution is a measure of the extent to which the drug distributes in the body. (NCT00594568)
Timeframe: 6 weeks, 12 weeks, and 52 weeks
| Intervention | liter (L) (Geometric Mean) |
|---|---|
| LY450139 | 66.8 |
Concentration of amino acid peptide, known as Aβ 1-42, in plasma. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator. (NCT00594568)
Timeframe: Baseline (randomization), 52 weeks
| Intervention | picogram per milliliter (pg/mL) (Least Squares Mean) |
|---|---|
| Placebo | 3.86 |
| 100 mg LY450139 | -5.97 |
| 140 mg LY450139 | -19.95 |
The vMRI assessment of left and right hippocampal volume is reported. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator. (NCT00594568)
Timeframe: Baseline (randomization), up to 76 weeks
| Intervention | cubic millimeter (mm^3) (Least Squares Mean) | |
|---|---|---|
| Left Hippocampal Volume | Right Hippocampal Volume | |
| 100 mg LY450139 | -75.34 | -93.89 |
| 140 mg LY450139 | -107.62 | -112.40 |
| Placebo | -96.54 | -108.69 |
ADAS-Cog14 is ADAS-Cog11 augmented with delayed free recall, digit cancellation, and maze completion measures. A score of 0 to 10 for delayed free recall and a conversion code of 0 to 5 for digit cancellation and maze completion provide total score ranges for this extended ADAS-Cog14 of 0 to 90. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, concomitant standard of care (SOC) medication. (NCT00762411)
Timeframe: Baseline (randomization), 16 weeks following treatment cessation
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | 6.00 |
| Placebo | 5.89 |
ADAS-Cog14 is ADAS-Cog11 augmented with delayed free recall, digit cancellation, and maze completion measures. A score of 0 to 10 for delayed free recall and a conversion code of 0 to 5 for digit cancellation and maze completion provide total score ranges for this extended ADAS-Cog14 of 0 to 90. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00762411)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | 9.23 |
| Placebo | 8.32 |
The cognitive subscale of ADAS (ADAS Cog11) consists of 11 items assessing areas of function most typically impaired in Alzheimer's disease (AD): orientation, verbal memory, language, and praxis. The scale ranges from 0 to 70, with higher scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00762411)
Timeframe: Baseline (randomization), 16 weeks following treatment cessation
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | 4.81 |
| Placebo | 4.85 |
The cognitive subscale of the ADAS (ADAS Cog11) was used as a primary efficacy measure and consists of 11 items assessing areas of function most typically impaired in Alzheimer's disease (AD): orientation, verbal memory, language, and praxis. The scale ranges from 0 to 70, with higher scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00762411)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | 7.37 |
| Placebo | 6.77 |
ADAS-Cog12 is ADAS-Cog11 augmented with delayed free recall measure, resulting in a total score ranging from 0 to 80. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00762411)
Timeframe: Baseline (randomization), 16 weeks following treatment cessation
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | 5.33 |
| Placebo | 5.14 |
ADAS-Cog12 is ADAS-Cog11 augmented with delayed free recall measure, resulting in a total score ranging from 0 to 80. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00762411)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | 10.09 |
| Placebo | 10.34 |
The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's caregiver. The ADCS-ADL measures both basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00762411)
Timeframe: Baseline (randomization), 16 weeks following treatment cessation
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | -8.88 |
| Placebo | -7.68 |
The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's caregiver. The ADCS-ADL measures both basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00762411)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | -10.49 |
| Placebo | -9.77 |
Concentration of an amino acid peptide known as Aβ 1-42 in spinal fluid. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator. (NCT00762411)
Timeframe: Baseline (randomization), up to 76 weeks
| Intervention | picogram per milliliter (pg/mL) (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | 19.20 |
| Placebo | -21.39 |
A radioactive tracer for PET that is a ligand for amyloid called [18F]-AV-45. This permits the visualization of amyloid in the brains of Alzheimer's participants. The outcome reported is the composite summary of the standard uptake value ratio (SUVR) normalized to the cerebellar gray matter. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator. (NCT00762411)
Timeframe: Baseline (randomization), up to 76 weeks
| Intervention | ratio (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | -0.36 |
| Placebo | 0.16 |
CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00762411)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | 3.05 |
| Placebo | 4.00 |
MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures) in elderly participants. Total score ranges from 0 to 30; lower score indicates greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication (NCT00762411)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | -3.56 |
| Placebo | -3.35 |
NPI assesses psychopathology in participants with dementia and other neurologic disorders. Information is obtained from a caregiver familiar with the participant's behavior. Total score ranges from 12 to 144; higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00762411)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | 2.94 |
| Placebo | 3.84 |
Concentration of p-tau in spinal fluid. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator. (NCT00762411)
Timeframe: Baseline (randomization), up to 76 weeks
| Intervention | picogram per milliliter (pg/mL) (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | 7.94 |
| Placebo | 14.75 |
Measurement of local cerebral glucose metabolism by PET using the radioactive tracer 18F-FDG. The outcome reported is the composite summary of the standard uptake value ratio (SUVR) normalized to the Pons. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator. (NCT00762411)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | ratio (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | -0.13 |
| Placebo | -0.08 |
Assess QoL for AD: participant rates mood, relationships, memory, finances, physical condition, and overall QoL assessment. Each of 13 items, rated on a 4-point scale. Sum of items=total score (range: 13 to 52). Higher scores indicate greater QoL. Participant's primary caregiver asked to complete same measure. Least Squares (LS) Mean value controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00762411)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | -1.83 |
| Placebo | -1.05 |
Concentration of total tau in spinal fluid. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator. (NCT00762411)
Timeframe: Baseline (randomization), up to 76 weeks
| Intervention | picogram per milliliter (pg/mL) (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | -11.60 |
| Placebo | 117.88 |
EQ-5D (proxy version) measures mobility, self-care, usual activities, pain/discomfort, anxiety/depression; each has 3 severity levels (no, some, severe problems) coded to a 1-digit number (1-3). Digits are combined into 5-digit number describing health state. Numerals 1-3 are not added for total score. VAS assesses caregiver's impression of participant's overall health state; scores range: 0 to 100. Lower scores indicate greater disease severity. Least Squares (LS) Mean value controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00762411)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | -4.46 |
| Placebo | -3.38 |
Assesses healthcare resource utilization (formal and informal care). Information gathered on both caregivers (care-giving time, work status) and participants (accommodation and healthcare resource utilization) was gathered from baseline and follow-up interviews. Reported number of hospitalizations per participant up to 76 weeks. Least Squares (LS) Mean value was controlled for age and investigator. (NCT00762411)
Timeframe: Baseline (randomization), up to 76 weeks
| Intervention | number of hospitalizations (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | 0.72 |
| Placebo | 0.82 |
Model estimated apparent oral clearance. Clearance is defined as the volume of plasma which is completely cleared of drug (LY450139) per unit time. (NCT00762411)
Timeframe: 6 weeks, 12 weeks, and 52 weeks
| Intervention | liters per hour (L/h) (Geometric Mean) |
|---|---|
| 140 mg LY450139 | 18.9 |
Model-estimated apparent volume of distribution. Volume of distribution is a measure of the extent to which drug distributes in the body. (NCT00762411)
Timeframe: 6 weeks, 12 weeks, and 52 weeks
| Intervention | liters (L) (Geometric Mean) |
|---|---|
| 140 mg LY450139 | 66.1 |
Concentration of amino acid peptide known as Aβ 1-42 in plasma. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator. (NCT00762411)
Timeframe: Baseline (randomization), 52 weeks
| Intervention | picogram per milliliter (pg/mL) (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | -16.03 |
| Placebo | 76.37 |
The vMRI assessment of right and left hippocampal volume is reported. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator. (NCT00762411)
Timeframe: Baseline (randomization), up to 76 weeks
| Intervention | cubic millimeter (mm^3) (Least Squares Mean) | |
|---|---|---|
| Right Hippocampal Volume | Left Hippocampal Volume | |
| 140 mg LY450139 | -158.50 | -84.41 |
| Placebo | -73.60 | -111.27 |
12 reviews available for alanine and Disease Exacerbation
| Article | Year |
|---|---|
New dopaminergic therapies for PD motor complications.
Topics: Alanine; Antiparkinson Agents; Apomorphine; Benzylamines; Delayed-Action Preparations; Disease Progr | 2022 |
Scientific research progress of COVID-19/SARS-CoV-2 in the first five months.
Topics: Adenosine Monophosphate; Alanine; Amides; Angiotensin-Converting Enzyme 2; Angiotensin-Converting En | 2020 |
Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antibodies, Monoclonal, Humanized | 2020 |
Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials.
Topics: Adenosine Monophosphate; Alanine; Antimetabolites; Antiviral Agents; Betacoronavirus; Coronavirus In | 2020 |
[Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)].
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Antibodies, Monoclonal; Antibodies, Monoc | 2021 |
[COVID-19: From a clinician's perspective.]
Topics: Adenosine Monophosphate; Alanine; COVID-19; Disease Progression; Extracorporeal Membrane Oxygenation | 2020 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVI | 2021 |
MTHFR C677T and A1298C polymorphisms were associated with bladder cancer risk and disease progression: a meta-analysis.
Topics: Alanine; Amino Acid Substitution; Carcinoma; Case-Control Studies; Cysteine; Disease Progression; Ge | 2013 |
Safinamide for the treatment of Parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Disease Progression; Dopamine; Dopamine Agents | 2014 |
Clinical pharmacology review of safinamide for the treatment of Parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Clinical Trials as Topic; Disease Progression; | 2015 |
Renal effects of novel antiretroviral drugs.
Topics: Adenine; Alanine; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Creatinine; Disease Progression; | 2017 |
Safinamide in the treatment of Parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Clinical Trials as Topic; Disease Progression; | 2010 |
6 trials available for alanine and Disease Exacerbation
| Article | Year |
|---|---|
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
Topics: Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Comorbidity; COV | 2022 |
A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antineoplastic Agents; Carcinoma; Disease Progression; Dise | 2017 |
Effect of Rebamipide on the Premalignant Progression of Chronic Gastritis: A Randomized Controlled Study.
Topics: Alanine; CDX2 Transcription Factor; Disease Progression; Female; Gastric Mucosa; Gastritis; Helicoba | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Alanine; Anti-Ulcer Agents; Disease Progression; Drug | 2011 |
Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications G
Topics: Alanine; Albuminuria; Amino Acid Substitution; Diabetic Nephropathies; Diabetic Retinopathy; Disease | 2008 |
41 other studies available for alanine and Disease Exacerbation
| Article | Year |
|---|---|
Early Use of Remdesivir and Risk of Disease Progression in Hospitalized Patients With Mild to Moderate COVID-19.
Topics: Adenosine Monophosphate; Alanine; COVID-19 Drug Treatment; Disease Progression; Humans; Pneumonia; P | 2022 |
The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Cobicistat; COVID-19 Drug Treatment; Cr | 2022 |
Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2022 |
Biomarkers for Duchenne muscular dystrophy progression: impact of age in the mdx tongue spared muscle.
Topics: Acetic Acid; Alanine; Animals; Creatine; Disease Progression; Glycerol; Isoleucine; Methionine; Mice | 2023 |
Quantitative metabolic biomarker analysis of mild cognitive impairment in eastern U.P. and Bihar population.
Topics: Aged; Alanine; Biomarkers; Blood Glucose; Blood Specimen Collection; Choline; Cognitive Dysfunction; | 2020 |
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Animals; Betacoronavirus; Bronchoalveolar Lavage Fluid; Coronaviru | 2020 |
Molecular characteristics associated with ferroptosis in hepatocellular carcinoma progression.
Topics: Activating Transcription Factor 3; Alanine; Carcinoma, Hepatocellular; Disease Progression; Ferropto | 2021 |
Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
Topics: Adenosine Monophosphate; Alanine; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antivira | 2021 |
Remdesivir for COVID-19 pneumonia: still undecided, but it might all be about adequate timing.
Topics: Adenosine Monophosphate; Airway Management; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Treat | 2021 |
COVID-19, a tale of two peaks: patients' characteristics, treatments, and clinical outcomes.
Topics: Adenosine Monophosphate; Adult; Age Distribution; Aged; Alanine; Antiviral Agents; COVID-19; COVID-1 | 2021 |
Prolonged persistence of SARS-CoV-2 infection during A+AVD therapy for classical Hodgkin's lymphoma: A case report.
Topics: Adenosine Monophosphate; Adult; Alanine; Amides; Antineoplastic Agents; Antineoplastic Combined Chem | 2021 |
Amino Acid Signature in Human Melanoma Cell Lines from Different Disease Stages.
Topics: Alanine; Amino Acids; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Huma | 2018 |
Molecular breath analysis supports altered amino acid metabolism in idiopathic pulmonary fibrosis.
Topics: Aged; Alanine; Amino Acids; Area Under Curve; Biomarkers; Breath Tests; Case-Control Studies; Diseas | 2019 |
ADAMTS13 predicts renal and cardiovascular events in type 2 diabetic patients and response to therapy.
Topics: ADAM Proteins; ADAMTS13 Protein; Aged; Alanine; Angiotensin-Converting Enzyme Inhibitors; Biomarkers | 2013 |
Real-time assessment of ¹³C metabolism reveals an early lactate increase in the brain of rats with acute liver failure.
Topics: Alanine; Animals; Brain; Carbon; Carbon Isotopes; Computer Systems; Disease Progression; Lactic Acid | 2015 |
The progression from a lower to a higher invasive stage of bladder cancer is associated with severe alterations in glucose and pyruvate metabolism.
Topics: Alanine; Alanine Transaminase; Cell Line, Tumor; Disease Progression; Glucose; Glucose Transporter T | 2015 |
Enhanced molecular mobility of ordinarily structured regions drives polyglutamine disease.
Topics: Alanine; Allosteric Site; Amyloidogenic Proteins; Ataxin-3; Benzothiazoles; Catalytic Domain; Chroma | 2015 |
Dynamic Changes in Striatal mGluR1 But Not mGluR5 during Pathological Progression of Parkinson's Disease in Human Alpha-Synuclein A53T Transgenic Rats: A Multi-PET Imaging Study.
Topics: Alanine; alpha-Synuclein; Animals; Corpus Striatum; Disease Models, Animal; Disease Progression; Exc | 2016 |
Serine 421 regulates mutant huntingtin toxicity and clearance in mice.
Topics: Alanine; Animals; Aspartic Acid; Behavior, Animal; Chromosomes, Artificial, Bacterial; Disease Model | 2016 |
Progressive neuropathology and cognitive decline in a single Arctic APP transgenic mouse model.
Topics: Age Factors; Alanine; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Anim | 2011 |
The proinflammatory action of microglial P2 receptors is enhanced in SOD1 models for amyotrophic lateral sclerosis.
Topics: Alanine; Amino Acid Substitution; Amyotrophic Lateral Sclerosis; Animals; Cell Line, Transformed; Ce | 2009 |
Molecular and clinical characterization of a novel SCN5A mutation associated with atrioventricular block and dilated cardiomyopathy.
Topics: Adult; Alanine; Amino Acid Substitution; Asian People; Atrioventricular Block; Base Sequence; Cardio | 2008 |
Deoxysphingoid bases as plasma markers in diabetes mellitus.
Topics: Aged; Alanine; Biomarkers; Body Mass Index; Case-Control Studies; Diabetes Mellitus, Type 2; Diabeti | 2010 |
Relationship between neuropathology and disease progression in the SOD1(G93A) ALS mouse.
Topics: Alanine; Amino Acid Substitution; Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Di | 2011 |
[Implication of platelet-activating factor receptor A224D mutation in susceptibility to relapsing-remitting multiple sclerosis: A Tunisian population study].
Topics: Adult; Alanine; Amino Acid Substitution; Aspartic Acid; Disease Progression; Female; Genetic Associa | 2012 |
Drugs: a tangled web of targets.
Topics: Alanine; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; An | 2011 |
PGC-1α protects neurons and alters disease progression in an amyotrophic lateral sclerosis mouse model.
Topics: Alanine; Amino Acid Substitution; Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Di | 2011 |
Urine metabolomics analysis for biomarker discovery and detection of jaundice syndrome in patients with liver disease.
Topics: Adult; Alanine; Aspartic Acid; Biomarkers; Chromatography, High Pressure Liquid; Disease Progression | 2012 |
CAG mutation effect on rate of progression in Huntington's disease.
Topics: Age of Onset; Alanine; Cysteine; Disease Progression; DNA Mutational Analysis; Female; Follow-Up Stu | 2002 |
Intravenous administration of human umbilical cord blood cells in a mouse model of amyotrophic lateral sclerosis: distribution, migration, and differentiation.
Topics: Alanine; Animals; Cord Blood Stem Cell Transplantation; Disease Models, Animal; Disease Progression; | 2003 |
Activated eIF4E-binding protein slows G1 progression and blocks transformation by c-myc without inhibiting cell growth.
Topics: Adaptor Proteins, Signal Transducing; Alanine; Animals; Carrier Proteins; Cell Cycle Proteins; Cell | 2004 |
CD24 is a genetic modifier for risk and progression of multiple sclerosis.
Topics: Alanine; Alleles; Animals; Antigens, CD; CD24 Antigen; CD3 Complex; Cell Membrane; Cloning, Molecula | 2003 |
Reduced reactivation rate in mutant CuZnSOD and progression rate of amyotrophic lateral sclerosis.
Topics: Alanine; Amyotrophic Lateral Sclerosis; Bacteria; Blotting, Western; Cloning, Molecular; Copper; Dis | 2004 |
The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Aged; Alanine; Alleles; Arginine; Biomarkers, Tumor; Case-Con | 2005 |
Late-onset mitochondrial myopathy with dystrophic changes due to a G7497A mutation in the mitochondrial tRNA(Ser(UCN)) gene.
Topics: Adult; Alanine; Disease Progression; DNA Mutational Analysis; DNA, Mitochondrial; Family Health; Fem | 2005 |
Prediction of progression to cirrhosis by a glutathione S-transferase P1 polymorphism in subjects with hereditary hemochromatosis.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Disease Progression; Female; Genotype; Glutathione Transfer | 2005 |
Early onset progressive ataxia associated with the first CACNA1A mutation identified within the I-II loop.
Topics: Alanine; Ataxia; Calcium Channels; Disease Progression; Humans; Mutation; Protein Structure, Tertiar | 2007 |
Early and sustained alterations in cerebral metabolism after traumatic brain injury in immature rats.
Topics: Aging; Alanine; Animals; Animals, Newborn; Aspartic Acid; Brain; Brain Injuries; Cell Respiration; C | 2008 |
Cardiac energy metabolism at several stages of adriamycin-induced heart failure in rats.
Topics: Adenosine Triphosphate; Alanine; Animals; Cardiac Output, Low; Carnitine; Chromatography, High Press | 1996 |
[Polyradiculoneuropathy in an adult with primitive hyperoxaluria].
Topics: Adult; Alanine; Biopsy; Disease Progression; Humans; Hyperoxaluria, Primary; Kidney Failure, Chronic | 2000 |
Hepatic transport of gluconeogenic substrates during tumor growth in the rat.
Topics: Alanine; Animals; Diffusion; Disease Progression; Female; Glucose; Glycerol; Kinetics; Lactic Acid; | 2001 |